Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide drug–drug interactions with morphine and edoxaban in prostate cancer
2024-517646-34-00Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of enzalutamide, morphine and edoxaban in prostate cancer (PCa), cancer pain and venous thromboembolism (VTE) (4 arms), sponsored by Radboud University Medical Center. Primary endpoints: Change in edoxaban and M4 exposure (AUC0-24hr) with or without enzalutamide and Change in morphine and morphine-6-glucuronide exposure (AUC0-12hr) with or without enzalutamide. Started Feb 2023; status: completed.
02
Drugs
enzalutamidemorphineedoxaban
03
Conditions
prostate cancer (PCa)cancer painvenous thromboembolism (VTE)
Beyond the preview
Go deeper on 2024-517646-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517646-34-00.